Download PDF
Erfahrungsheilkunde 2013; 62(5): 260-265
DOI: 10.1055/s-0033-1357543
Wissen
© Karl F. Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Sojaextrakte bei gynäkologischen Tumoren

Johannes Huber
Further Information

Publication History

Publication Date:
24 October 2013 (online)

    Permissions and Reprints

Zusammenfassung

Lange wurde das Östrogen Estradiol als das große Gift des weiblichen Körpers angesehen, und auch Pflanzenöstrogene galten als bedenklich. Aktuelle Studien belegen nicht nur das Gegenteil, sondern die in Soja enthaltenen Phytohormone haben sogar protektive Effekte. Der Schutzmechanismus korreliert aber v. a. mit der Konzentration im Blut. Neben dem Einfluss der Östrogenrezeptoren erläutert der Autor den Metabolismus des Hormons und erklärt die Effekte von Sojaextrakt auf onkologische Vorgänge.

Abstract

For a long time, the estrogen estradiol has been regarded as the major poison of the female body and even vegetable estrogens were considered to be suspicious. Present studies not only prove the opposite, they also show, that the phytohormones contained in soy have protective effects. The protective mechanism however correlates especially with the concentration in the blood. In addition to the influence of the estrogen receptors, the author illustrates the metabolism of the hormone and explains the effect, soy extract has on oncological processes.

Schlüsselwörter

Sojaextrakte - gynäkologische Tumoren - Phytoöstrogene - Estrogenrezeptoren - Metabolisierung

Keywords

Soy extracts - gynecological tumors - phytoestrogens - estrogen receptors - metabolization
 

  • Literatur

  • 1 Anandanadesan R, Gong Q, Chipitsyna G et al. Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling. J Gastrointest Surg 2008; 12 (1): 57-66
    CrossrefPubMedGoogle Scholar
  • 2 Atkinson et al. 2004; Marini et al. 2008; Maskarinec et al. 2003; Maskarinec et al. 2009; Powles et al. 2008; Verheus et al. 2008
    PubMed
  • 3 Boucher BA, Cotterchio M, Anderson LN, Kreiger N, Kirsh VA, Thompson LU. Use of isoflavone supplements is associated with reduced postmenopausal breast cancer risk. Int J Cancer 2013; 132 (6): 1439-1450
    CrossrefPubMedGoogle Scholar
  • 4 Buck K, Vrieling A, Zaineddin AK et al. Serum enterolactone and prognosis of postmenopausal breast cancer. Journal of Clinical Oncology 2011; DOI: 10.1200/JCO.2011.34.6478.
    PubMedGoogle Scholar
  • 5 Guo Y, Wang S, Hoot DR et al. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. J Nutr Biochem 2007; 18 (6): 408-417
    CrossrefPubMedGoogle Scholar
  • 6 Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS Jr. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000; 289 (5488): 2363-2366
    CrossrefPubMedGoogle Scholar
  • 7 Hooper L et al. Effects of soy protein and isoflavones on circulating hormone concentrations in pre- and post-menopausal women: a systematic review and meta-analysis. Hum Reprod Update 2009; 15 (4): 423-440
    CrossrefPubMedGoogle Scholar
  • 8 Iwasaki M, Inoue M, Otani T et al. Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group. J Clin Oncol 2008; 26 (10): 1677-1683
    CrossrefPubMedGoogle Scholar
  • 9 Kang X, Zhang Q, Wang S et al. Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy. CMAJ 2010; DOI: 10.1503/cmaj.091298.
    PubMedGoogle Scholar
  • 10 Magee PJ, Rowland I. Soy products in the management of breast cancer. Curr Opin Clin Nutr Metab Care 2012; 15 (6): 586-591
    CrossrefPubMedGoogle Scholar
  • 11 Myung SK, Ju W, Choi HJ, Kim SC. Korean Meta-Analysis (KORMA) Study Group. Soy intake and risk of endocrine-related gynaecological cancer: a meta-analysis. BJOG 2009; 116 (13): 1697-1705
    CrossrefPubMedGoogle Scholar
  • 12 Sarkar FH, Adsule S, Padhye S, Kulkarni S, Li Y. The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini Rev Med Chem 2006; 6 (4): 401-407
    CrossrefPubMedGoogle Scholar
  • 13 Shu XO. Soy food intake among breast cancer patients: Association with survival and menopausal symptoms. 9th International Symposium on the Role of Soy in Health Promotion and Chronic Disease Prevention and Treatment, Washington DC, 2010
    PubMedGoogle Scholar
  • 14 Small GW, Shi YY, Higgins LS et al. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 2007; 67 (9): 4459-4466
    CrossrefPubMedGoogle Scholar
  • 15 Teas J et al. Dietary seaweed modifies estrogen and phytoestrogen metabolism in healthy postmenopausal women. J Nutr 2009; 139 (5): 939-944
    CrossrefPubMedGoogle Scholar
  • 16 Tempfer CB, Bentz EK, Huber JC et al. Phytoestrogens in clinical practice: a review of the literature. Fertil Steril 2007; 87 (6): 1243-1249
    CrossrefPubMedGoogle Scholar
  • 17 Vanden Berghe W, Dijsselbloem N, Vermeulen L et al. Attenuation of mitogen- and stress-activated protein kinase-1-driven nuclear factor-kappaB gene expression by soy isoflavones does not require estrogenic activity. Cancer Res 2006; 66 (9): 4852-4862
    CrossrefPubMedGoogle Scholar
  • 18 Verheus M, van Gils CH, Keinan-Boker L et al. Plasma phytoestrogens and subsequent breast cancer risk. J Clin Oncol 2007; 25 (6): 648-655
    CrossrefPubMedGoogle Scholar
  • 19 Zamora-Ros R, Ferrari P, González CA et al. Dietary flavonoid and lignan intake and breast cancer risk according to menopause and hormone receptor status in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study. Breast Cancer Res Treat 2013; 139 (1): 163-176
    CrossrefPubMedGoogle Scholar